Ontology highlight
ABSTRACT:
SUBMITTER: Sherbenou DW
PROVIDER: S-EPMC2995357 | biostudies-literature | 2010 Oct
REPOSITORIES: biostudies-literature
Sherbenou Daniel W DW Hantschel Oliver O Kaupe Ines I Willis Stephanie S Bumm Thomas T Turaga Lalita P LP Lange Thoralf T Dao Kim-Hien KH Press Richard D RD Druker Brian J BJ Superti-Furga Giulio G Deininger Michael W MW
Blood 20100602 17
Point mutations in the kinase domain of BCR-ABL are the most common mechanism of drug resistance in chronic myeloid leukemia (CML) patients treated with ABL kinase inhibitors, including imatinib. It has also been shown in vitro that mutations outside the kinase domain in the neighboring linker, SH2, SH3, and Cap domains can confer imatinib resistance. In the context of ABL, these domains have an autoinhibitory effect on kinase activity, and mutations in this region can activate the enzyme. To de ...[more]